STOCK TITAN

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Harrow (Nasdaq: HROW) will release its first quarter 2024 financial results on May 13, 2024, followed by a conference call on May 14, 2024, to discuss the results and provide a business update.
Harrow (Nasdaq: HROW) pubblicherà i risultati finanziari del primo trimestre del 2024 il 13 maggio 2024, seguiti da una conferenza telefonica il 14 maggio 2024 per discutere i risultati e fornire un aggiornamento sull'attività.
Harrow (Nasdaq: HROW) publicará los resultados financieros del primer trimestre de 2024 el 13 de mayo de 2024, seguido por una llamada de conferencia el 14 de mayo de 2024 para discutir los resultados y proporcionar una actualización del negocio.
Harrow (나스닥: HROW)는 2024년 5월 13일에 2024년도 1분기 재무 결과를 발표할 예정이며, 그 다음날인 5월 14일에 결과를 논의하고 사업 업데이트를 제공하기 위한 컨퍼런스 콜을 진행할 예정입니다.
Harrow (Nasdaq: HROW) publiera ses résultats financiers pour le premier trimestre 2024 le 13 mai 2024, suivi par une conférence téléphonique le 14 mai 2024 pour discuter des résultats et fournir une mise à jour sur les activités.
Harrow (Nasdaq: HROW) wird am 13. Mai 2024 die Finanzergebnisse des ersten Quartals 2024 veröffentlichen, gefolgt von einer Telefonkonferenz am 14. Mai 2024, um die Ergebnisse zu diskutieren und ein Geschäftsupdate zu geben.
Positive
  • None.
Negative
  • None.

Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on May 14, 2024

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 14, 2024, to discuss the results and provide a business update.

Conference Call Details:  

  

Date:

 

Tuesday, May 14, 2024

Time:

 

8:00 a.m. Eastern time

Participant Dial-in:

 

1-833-953-2434 (U.S.)
1-412-317-5763 (International)

Replay Dial-in (Passcode 3093849):

(telephonic replay through May 21, 2024)

 

1-877-344-7529 (U.S.)
1-412-317-0088 (International)

Webcast: (online replay through May 14, 2025)

 

harrow.com

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.

Jamie Webb

Director of Communications and Investor Relations

jwebb@harrowinc.com

615-733-4737

Source: Harrow, Inc.

FAQ

When will Harrow release its first quarter 2024 financial results?

Harrow will release its first quarter 2024 financial results on May 13, 2024.

What is the date of the conference call to discuss the financial results?

The conference call to discuss the financial results will take place on May 14, 2024.

What time will the conference call be held?

The conference call will be held at 8:00 a.m. Eastern Time on May 14, 2024.

Where can investors find the first quarter Letter to Stockholders?

Investors can find the first quarter Letter to Stockholders on the 'Investors' section of Harrow's website, harrow.com.

What are the participant dial-in numbers for the conference call?

The participant dial-in numbers for the conference call are 1-833-953-2434 (U.S.) and 1-412-317-5763 (International).

Harrow, Inc.

NASDAQ:HROW

HROW Rankings

HROW Latest News

HROW Stock Data

367.26M
26.55M
14.59%
66.11%
17.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NASHVILLE

About HROW

harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas